# A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

> **NCT05387083** · PHASE2 · COMPLETED · sponsor: **Tarsus Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Low Dose TP-05
- **DRUG:** High Dose TP-05
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT05387083
- **Lead sponsor:** Tarsus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-12
- **Primary completion:** 2024-06-26
- **Final completion:** 2024-06-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387083, "A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05387083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*